Vitamin K2 administration is associated with decreased disease activity in patients with rheumatoid arthritis
Abstract Objectives Vitamin K2 (VitK2) is reported to induce not only bone mineralization of human osteoblasts and apoptosis of osteoclasts, but also apoptosis of rheumatoid arthritis (RA) synovial cells, while its clinical effect on disease activity of RA remains unknown. Methods 158 female RA pati...
Gespeichert in:
| Veröffentlicht in: | Modern rheumatology 2013-09, Vol.23 (5), p.1001-1007 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1007 |
|---|---|
| container_issue | 5 |
| container_start_page | 1001 |
| container_title | Modern rheumatology |
| container_volume | 23 |
| creator | Ebina, Kosuke Shi, Kenrin Hirao, Makoto Kaneshiro, Shoichi Morimoto, Tokimitsu Koizumi, Kota Yoshikawa, Hideki Hashimoto, Jun |
| description | Abstract
Objectives Vitamin K2 (VitK2) is reported to induce not only bone mineralization of human osteoblasts and apoptosis of osteoclasts, but also apoptosis of rheumatoid arthritis (RA) synovial cells, while its clinical effect on disease activity of RA remains unknown.
Methods 158 female RA patients (mean age 62.5 years) who had not been treated with warfarin, biologics, or teriparatide were enrolled in this study. VitK2 (45 mg/day) was administered in 70 patients with a serum undercarboxylated osteocalcin level of >4.5 ng/ml or with decreased bone mineral density in spite of the treatment with other anti-osteoporosis medications, regardless of RA disease activity. A longitudinal study was conducted in 52 patients who were additionally treated with VitK2 without changing their other medications for three months.
Results In the cross-sectional study, as compared to the VitK2-naïve group (n = 88), the VitK2-treated group (n = 70) showed lower serum CRP (1.7 ± 0.2 vs. 0.5 ± 0.1 mg/dl; P < 0.001), MMP-3 (220.4 ± 21.9 vs. 118.0 ± 14.4 ng/ml; P < 0.001), and DAS28-CRP (2.9 ± 0.1 vs. 2.4 ± 0.1; P < 0.05). In the longitudinal study, patients who were additionally treated with VitK2 showed significant decreases in serum CRP (1.1 ± 0.2 to 0.6 ± 0.2 mg/dl; P < 0.001), MMP-3 (160.1 ± 25.6 to 125.0 ± 17.8 ng/ml; P < 0.05), and DAS28-CRP (3.1 ± 0.2 to 2.4 ± 0.1; P < 0.001).
Conclusions VitK2 may have the potential to improve disease activity besides osteoporosis in RA. |
| doi_str_mv | 10.3109/s10165-012-0789-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_23124653</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3083549251</sourcerecordid><originalsourceid>FETCH-LOGICAL-c427t-cdae8850fde49bffd202bf7acee93beb6693885157d75e5a9e7e66fdffca5f733</originalsourceid><addsrcrecordid>eNp1kM1rFTEUxYMotlb_ADcScD2aj8lkgm6k-IUFN-o23ElumJQ3k2eS1_L-e_OYVnTR1T2XnHMu-RHykrM3kjPztnDGB9UxLjqmR9P1j8g576Xp9MDM43utjDojz0q5ZkwqM5qn5ExILvpByXOy_IoVlrjSb4KCbyKWmqHGtNJYKJSSXISKnt7GOlOPLiOUtvpYToKCq_Em1iNtFfuWw7WWzZtnPCxQU_QUcp1zrLE8J08C7Aq-uJsX5Oenjz8uv3RX3z9_vfxw1ble6No5DziOigWPvZlC8IKJKWhwiEZOOA2Dke2dK-21QgUGNQ5D8CE4UEFLeUFeb737nH4fsFR7nQ55bSdtY6KFGBuK5uKby-VUSsZg9zkukI-WM3sCbDfAtgG2J8C2b5lXd82HaUH_N3FPtBneb4a4hpQXuE15522F4y7lkGF1sZy6H-5_9198RtjV2UHGf77wYPoPRS2gkA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1437228035</pqid></control><display><type>article</type><title>Vitamin K2 administration is associated with decreased disease activity in patients with rheumatoid arthritis</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Ebina, Kosuke ; Shi, Kenrin ; Hirao, Makoto ; Kaneshiro, Shoichi ; Morimoto, Tokimitsu ; Koizumi, Kota ; Yoshikawa, Hideki ; Hashimoto, Jun</creator><creatorcontrib>Ebina, Kosuke ; Shi, Kenrin ; Hirao, Makoto ; Kaneshiro, Shoichi ; Morimoto, Tokimitsu ; Koizumi, Kota ; Yoshikawa, Hideki ; Hashimoto, Jun</creatorcontrib><description><![CDATA[Abstract
Objectives Vitamin K2 (VitK2) is reported to induce not only bone mineralization of human osteoblasts and apoptosis of osteoclasts, but also apoptosis of rheumatoid arthritis (RA) synovial cells, while its clinical effect on disease activity of RA remains unknown.
Methods 158 female RA patients (mean age 62.5 years) who had not been treated with warfarin, biologics, or teriparatide were enrolled in this study. VitK2 (45 mg/day) was administered in 70 patients with a serum undercarboxylated osteocalcin level of >4.5 ng/ml or with decreased bone mineral density in spite of the treatment with other anti-osteoporosis medications, regardless of RA disease activity. A longitudinal study was conducted in 52 patients who were additionally treated with VitK2 without changing their other medications for three months.
Results In the cross-sectional study, as compared to the VitK2-naïve group (n = 88), the VitK2-treated group (n = 70) showed lower serum CRP (1.7 ± 0.2 vs. 0.5 ± 0.1 mg/dl; P < 0.001), MMP-3 (220.4 ± 21.9 vs. 118.0 ± 14.4 ng/ml; P < 0.001), and DAS28-CRP (2.9 ± 0.1 vs. 2.4 ± 0.1; P < 0.05). In the longitudinal study, patients who were additionally treated with VitK2 showed significant decreases in serum CRP (1.1 ± 0.2 to 0.6 ± 0.2 mg/dl; P < 0.001), MMP-3 (160.1 ± 25.6 to 125.0 ± 17.8 ng/ml; P < 0.05), and DAS28-CRP (3.1 ± 0.2 to 2.4 ± 0.1; P < 0.001).
Conclusions VitK2 may have the potential to improve disease activity besides osteoporosis in RA.]]></description><identifier>ISSN: 1439-7595</identifier><identifier>EISSN: 1439-7609</identifier><identifier>DOI: 10.3109/s10165-012-0789-4</identifier><identifier>PMID: 23124653</identifier><language>eng</language><publisher>United States: Informa Healthcare</publisher><subject>Aged ; Apoptosis ; Arthritis, Rheumatoid - blood ; Arthritis, Rheumatoid - drug therapy ; Bone Density - drug effects ; C-reactive protein ; Cells ; Cross-Sectional Studies ; Disease Activity Score assessing 28 joints with CRP ; Female ; Humans ; Longitudinal Studies ; Matrix metalloproteinase-3 ; Medical treatment ; Middle Aged ; Osteocalcin - blood ; Osteoporosis ; Rheumatoid arthritis ; Rheumatology ; Severity of Illness Index ; Treatment Outcome ; Vitamin K 2 - pharmacology ; Vitamin K 2 - therapeutic use ; Vitamin K2 ; Vitamins</subject><ispartof>Modern rheumatology, 2013-09, Vol.23 (5), p.1001-1007</ispartof><rights>2013 Japan College of Rheumatology 2013</rights><rights>Copyright Springer Science & Business Media Sep 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c427t-cdae8850fde49bffd202bf7acee93beb6693885157d75e5a9e7e66fdffca5f733</citedby><cites>FETCH-LOGICAL-c427t-cdae8850fde49bffd202bf7acee93beb6693885157d75e5a9e7e66fdffca5f733</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23124653$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ebina, Kosuke</creatorcontrib><creatorcontrib>Shi, Kenrin</creatorcontrib><creatorcontrib>Hirao, Makoto</creatorcontrib><creatorcontrib>Kaneshiro, Shoichi</creatorcontrib><creatorcontrib>Morimoto, Tokimitsu</creatorcontrib><creatorcontrib>Koizumi, Kota</creatorcontrib><creatorcontrib>Yoshikawa, Hideki</creatorcontrib><creatorcontrib>Hashimoto, Jun</creatorcontrib><title>Vitamin K2 administration is associated with decreased disease activity in patients with rheumatoid arthritis</title><title>Modern rheumatology</title><addtitle>Mod Rheumatol</addtitle><description><![CDATA[Abstract
Objectives Vitamin K2 (VitK2) is reported to induce not only bone mineralization of human osteoblasts and apoptosis of osteoclasts, but also apoptosis of rheumatoid arthritis (RA) synovial cells, while its clinical effect on disease activity of RA remains unknown.
Methods 158 female RA patients (mean age 62.5 years) who had not been treated with warfarin, biologics, or teriparatide were enrolled in this study. VitK2 (45 mg/day) was administered in 70 patients with a serum undercarboxylated osteocalcin level of >4.5 ng/ml or with decreased bone mineral density in spite of the treatment with other anti-osteoporosis medications, regardless of RA disease activity. A longitudinal study was conducted in 52 patients who were additionally treated with VitK2 without changing their other medications for three months.
Results In the cross-sectional study, as compared to the VitK2-naïve group (n = 88), the VitK2-treated group (n = 70) showed lower serum CRP (1.7 ± 0.2 vs. 0.5 ± 0.1 mg/dl; P < 0.001), MMP-3 (220.4 ± 21.9 vs. 118.0 ± 14.4 ng/ml; P < 0.001), and DAS28-CRP (2.9 ± 0.1 vs. 2.4 ± 0.1; P < 0.05). In the longitudinal study, patients who were additionally treated with VitK2 showed significant decreases in serum CRP (1.1 ± 0.2 to 0.6 ± 0.2 mg/dl; P < 0.001), MMP-3 (160.1 ± 25.6 to 125.0 ± 17.8 ng/ml; P < 0.05), and DAS28-CRP (3.1 ± 0.2 to 2.4 ± 0.1; P < 0.001).
Conclusions VitK2 may have the potential to improve disease activity besides osteoporosis in RA.]]></description><subject>Aged</subject><subject>Apoptosis</subject><subject>Arthritis, Rheumatoid - blood</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Bone Density - drug effects</subject><subject>C-reactive protein</subject><subject>Cells</subject><subject>Cross-Sectional Studies</subject><subject>Disease Activity Score assessing 28 joints with CRP</subject><subject>Female</subject><subject>Humans</subject><subject>Longitudinal Studies</subject><subject>Matrix metalloproteinase-3</subject><subject>Medical treatment</subject><subject>Middle Aged</subject><subject>Osteocalcin - blood</subject><subject>Osteoporosis</subject><subject>Rheumatoid arthritis</subject><subject>Rheumatology</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><subject>Vitamin K 2 - pharmacology</subject><subject>Vitamin K 2 - therapeutic use</subject><subject>Vitamin K2</subject><subject>Vitamins</subject><issn>1439-7595</issn><issn>1439-7609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1rFTEUxYMotlb_ADcScD2aj8lkgm6k-IUFN-o23ElumJQ3k2eS1_L-e_OYVnTR1T2XnHMu-RHykrM3kjPztnDGB9UxLjqmR9P1j8g576Xp9MDM43utjDojz0q5ZkwqM5qn5ExILvpByXOy_IoVlrjSb4KCbyKWmqHGtNJYKJSSXISKnt7GOlOPLiOUtvpYToKCq_Em1iNtFfuWw7WWzZtnPCxQU_QUcp1zrLE8J08C7Aq-uJsX5Oenjz8uv3RX3z9_vfxw1ble6No5DziOigWPvZlC8IKJKWhwiEZOOA2Dke2dK-21QgUGNQ5D8CE4UEFLeUFeb737nH4fsFR7nQ55bSdtY6KFGBuK5uKby-VUSsZg9zkukI-WM3sCbDfAtgG2J8C2b5lXd82HaUH_N3FPtBneb4a4hpQXuE15522F4y7lkGF1sZy6H-5_9198RtjV2UHGf77wYPoPRS2gkA</recordid><startdate>201309</startdate><enddate>201309</enddate><creator>Ebina, Kosuke</creator><creator>Shi, Kenrin</creator><creator>Hirao, Makoto</creator><creator>Kaneshiro, Shoichi</creator><creator>Morimoto, Tokimitsu</creator><creator>Koizumi, Kota</creator><creator>Yoshikawa, Hideki</creator><creator>Hashimoto, Jun</creator><general>Informa Healthcare</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope></search><sort><creationdate>201309</creationdate><title>Vitamin K2 administration is associated with decreased disease activity in patients with rheumatoid arthritis</title><author>Ebina, Kosuke ; Shi, Kenrin ; Hirao, Makoto ; Kaneshiro, Shoichi ; Morimoto, Tokimitsu ; Koizumi, Kota ; Yoshikawa, Hideki ; Hashimoto, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c427t-cdae8850fde49bffd202bf7acee93beb6693885157d75e5a9e7e66fdffca5f733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Apoptosis</topic><topic>Arthritis, Rheumatoid - blood</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Bone Density - drug effects</topic><topic>C-reactive protein</topic><topic>Cells</topic><topic>Cross-Sectional Studies</topic><topic>Disease Activity Score assessing 28 joints with CRP</topic><topic>Female</topic><topic>Humans</topic><topic>Longitudinal Studies</topic><topic>Matrix metalloproteinase-3</topic><topic>Medical treatment</topic><topic>Middle Aged</topic><topic>Osteocalcin - blood</topic><topic>Osteoporosis</topic><topic>Rheumatoid arthritis</topic><topic>Rheumatology</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><topic>Vitamin K 2 - pharmacology</topic><topic>Vitamin K 2 - therapeutic use</topic><topic>Vitamin K2</topic><topic>Vitamins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ebina, Kosuke</creatorcontrib><creatorcontrib>Shi, Kenrin</creatorcontrib><creatorcontrib>Hirao, Makoto</creatorcontrib><creatorcontrib>Kaneshiro, Shoichi</creatorcontrib><creatorcontrib>Morimoto, Tokimitsu</creatorcontrib><creatorcontrib>Koizumi, Kota</creatorcontrib><creatorcontrib>Yoshikawa, Hideki</creatorcontrib><creatorcontrib>Hashimoto, Jun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Modern rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ebina, Kosuke</au><au>Shi, Kenrin</au><au>Hirao, Makoto</au><au>Kaneshiro, Shoichi</au><au>Morimoto, Tokimitsu</au><au>Koizumi, Kota</au><au>Yoshikawa, Hideki</au><au>Hashimoto, Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vitamin K2 administration is associated with decreased disease activity in patients with rheumatoid arthritis</atitle><jtitle>Modern rheumatology</jtitle><addtitle>Mod Rheumatol</addtitle><date>2013-09</date><risdate>2013</risdate><volume>23</volume><issue>5</issue><spage>1001</spage><epage>1007</epage><pages>1001-1007</pages><issn>1439-7595</issn><eissn>1439-7609</eissn><abstract><![CDATA[Abstract
Objectives Vitamin K2 (VitK2) is reported to induce not only bone mineralization of human osteoblasts and apoptosis of osteoclasts, but also apoptosis of rheumatoid arthritis (RA) synovial cells, while its clinical effect on disease activity of RA remains unknown.
Methods 158 female RA patients (mean age 62.5 years) who had not been treated with warfarin, biologics, or teriparatide were enrolled in this study. VitK2 (45 mg/day) was administered in 70 patients with a serum undercarboxylated osteocalcin level of >4.5 ng/ml or with decreased bone mineral density in spite of the treatment with other anti-osteoporosis medications, regardless of RA disease activity. A longitudinal study was conducted in 52 patients who were additionally treated with VitK2 without changing their other medications for three months.
Results In the cross-sectional study, as compared to the VitK2-naïve group (n = 88), the VitK2-treated group (n = 70) showed lower serum CRP (1.7 ± 0.2 vs. 0.5 ± 0.1 mg/dl; P < 0.001), MMP-3 (220.4 ± 21.9 vs. 118.0 ± 14.4 ng/ml; P < 0.001), and DAS28-CRP (2.9 ± 0.1 vs. 2.4 ± 0.1; P < 0.05). In the longitudinal study, patients who were additionally treated with VitK2 showed significant decreases in serum CRP (1.1 ± 0.2 to 0.6 ± 0.2 mg/dl; P < 0.001), MMP-3 (160.1 ± 25.6 to 125.0 ± 17.8 ng/ml; P < 0.05), and DAS28-CRP (3.1 ± 0.2 to 2.4 ± 0.1; P < 0.001).
Conclusions VitK2 may have the potential to improve disease activity besides osteoporosis in RA.]]></abstract><cop>United States</cop><pub>Informa Healthcare</pub><pmid>23124653</pmid><doi>10.3109/s10165-012-0789-4</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1439-7595 |
| ispartof | Modern rheumatology, 2013-09, Vol.23 (5), p.1001-1007 |
| issn | 1439-7595 1439-7609 |
| language | eng |
| recordid | cdi_pubmed_primary_23124653 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Aged Apoptosis Arthritis, Rheumatoid - blood Arthritis, Rheumatoid - drug therapy Bone Density - drug effects C-reactive protein Cells Cross-Sectional Studies Disease Activity Score assessing 28 joints with CRP Female Humans Longitudinal Studies Matrix metalloproteinase-3 Medical treatment Middle Aged Osteocalcin - blood Osteoporosis Rheumatoid arthritis Rheumatology Severity of Illness Index Treatment Outcome Vitamin K 2 - pharmacology Vitamin K 2 - therapeutic use Vitamin K2 Vitamins |
| title | Vitamin K2 administration is associated with decreased disease activity in patients with rheumatoid arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T03%3A21%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vitamin%20K2%20administration%20is%20associated%20with%20decreased%20disease%20activity%20in%20patients%20with%20rheumatoid%20arthritis&rft.jtitle=Modern%20rheumatology&rft.au=Ebina,%20Kosuke&rft.date=2013-09&rft.volume=23&rft.issue=5&rft.spage=1001&rft.epage=1007&rft.pages=1001-1007&rft.issn=1439-7595&rft.eissn=1439-7609&rft_id=info:doi/10.3109/s10165-012-0789-4&rft_dat=%3Cproquest_pubme%3E3083549251%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1437228035&rft_id=info:pmid/23124653&rfr_iscdi=true |